GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aclaris Therapeutics Inc (NAS:ACRS) » Definitions » Gross Margin %

Aclaris Therapeutics (Aclaris Therapeutics) Gross Margin % : 23.27% (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Aclaris Therapeutics Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Aclaris Therapeutics's Gross Profit for the three months ended in Mar. 2024 was $0.56 Mil. Aclaris Therapeutics's Revenue for the three months ended in Mar. 2024 was $2.40 Mil. Therefore, Aclaris Therapeutics's Gross Margin % for the quarter that ended in Mar. 2024 was 23.27%.


The historical rank and industry rank for Aclaris Therapeutics's Gross Margin % or its related term are showing as below:

ACRS' s Gross Margin % Range Over the Past 10 Years
Min: 4.07   Med: 29.62   Max: 59.8
Current: 41.99


During the past 11 years, the highest Gross Margin % of Aclaris Therapeutics was 59.80%. The lowest was 4.07%. And the median was 29.62%.

ACRS's Gross Margin % is ranked worse than
54.72% of 212 companies
in the Medical Diagnostics & Research industry
Industry Median: 46.675 vs ACRS: 41.99

Aclaris Therapeutics had a gross margin of 23.27% for the quarter that ended in Mar. 2024 => Competition eroding margins

The 5-Year average Growth Rate of Gross Margin for Aclaris Therapeutics was 33.80% per year.


Aclaris Therapeutics Gross Margin % Historical Data

The historical data trend for Aclaris Therapeutics's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aclaris Therapeutics Gross Margin % Chart

Aclaris Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.07 20.81 30.29 59.80 42.14

Aclaris Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.07 14.82 11.74 63.41 23.27

Competitive Comparison of Aclaris Therapeutics's Gross Margin %

For the Diagnostics & Research subindustry, Aclaris Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aclaris Therapeutics's Gross Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aclaris Therapeutics's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Aclaris Therapeutics's Gross Margin % falls into.



Aclaris Therapeutics Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Aclaris Therapeutics's Gross Margin for the fiscal year that ended in Dec. 2023 is calculated as

Gross Margin % (A: Dec. 2023 )=Gross Profit (A: Dec. 2023 ) / Revenue (A: Dec. 2023 )
=13.2 / 31.249
=(Revenue - Cost of Goods Sold) / Revenue
=(31.249 - 18.081) / 31.249
=42.14 %

Aclaris Therapeutics's Gross Margin for the quarter that ended in Mar. 2024 is calculated as


Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=0.6 / 2.398
=(Revenue - Cost of Goods Sold) / Revenue
=(2.398 - 1.84) / 2.398
=23.27 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Aclaris Therapeutics  (NAS:ACRS) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Aclaris Therapeutics had a gross margin of 23.27% for the quarter that ended in Mar. 2024 => Competition eroding margins


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Aclaris Therapeutics Gross Margin % Related Terms

Thank you for viewing the detailed overview of Aclaris Therapeutics's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aclaris Therapeutics (Aclaris Therapeutics) Business Description

Traded in Other Exchanges
Address
640 Lee Road, Suite 200, Wayne, PA, USA, 19087
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
Executives
Joseph Monahan officer: Chief Scientific Officer C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Kevin Balthaser officer: Chief Financial Officer C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
James Loerop officer: Chief Business Officer C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Douglas J. Manion officer: Pres and COO C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Neal Walker director, officer: President and CEO 15 NEW ENGLAND EXECUTIVE PARK, BURLINGTON MA 01803
Andrew N Schiff director PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022
Gail Cawkwell officer: Chief Medical Officer C/O ACLARIS THERAPEUTICS, INC., 640 LEE ROAD, SUITE 200, WAYNE PA 19087
Frank Ruffo officer: Chief Financial Officer C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
David N. Gordon officer: Chief Medical Officer C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
Kamil Ali-jackson officer: Chief Legal Officer C/O ACLARIS THERAPEUTICS, INC., 101 LINDENWOOD DRIVE, SUITE 400, MALVERN PA 19355
James B. Tananbaum 10 percent owner 3052 PACIFIC AVENUE, SAN FRANCISCO CA 94115
Foresite Capital Management Iii, Llc 10 percent owner 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939
Foresite Capital Fund Iii, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Fund Iv, L.p. 10 percent owner 600 MONTGOMERY STREET, SUITE 4500, SAN FRANCISCO CA 94111
Foresite Capital Management Iv, Llc 10 percent owner 900 LARKSPUR LANDING CIRCLE, SUITE 150, LARKSPUR CA 94939